Go Pro

Stock Analyst Initiations

Track the latest stock analyst initiations, newly initiated coverage, and first-time analyst ratings in this regularly updated list of analyst recommendations. This page compiles new initiations, including initial stock ratings, buy/hold/sell recommendations, and price targets, so you can monitor all recent coverage openings across the market.

CompanyActionBrokerageAnalystCurrent PricePrice TargetRatingDetails
Airbnb, Inc. stock logo
ABNB
Airbnb
Initiated by$169.72
+0.8%
$170.00Equal Weight
American Bitcoin Corp. stock logo
ABTC
American Bitcoin
Initiated by$8.07
+1.1%
$15.00Buy
Bandwidth Inc. stock logo
BAND
Bandwidth
Initiated by$49.77
-0.6%
$60.00Neutral
Five9, Inc. stock logo
FIVN
Five9
Initiated by$34.02
+3.0%
$40.00Outperform
Sensei Biotherapeutics, Inc. stock logo
FTH
Sensei Biotherapeutics
Initiated by$35.51
+0.4%
$70.00Buy
JAN stock logo
JAN
JAN
Initiated by$31.15
-1.4%
$37.00Neutral
KBC Group SA stock logo
KBCSY
KBC Group
Initiated by $76.25
+0.7%
Buy
MP Materials Corp. stock logo
MP
MP Materials
Initiated by$49.26
+0.2%
$57.00Hold
Pinnacle Financial Partners, Inc. stock logo
PNFP
Pinnacle Financial Partners
Initiated by $98.80
-0.5%
$125.00Outperform
Arcus Biosciences, Inc. stock logo
RCUS
Arcus Biosciences
Initiated by$24.91
+2.4%
Buy
Trump goes "all-in" on Grand Canyon energy breakthrough (Ad)

A drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of Saudi Arabia's largest oil field, with potential to last two million years. While the One Big Beautiful Bill Act eliminated federal credits for solar, wind, and EVs, this energy source was reclassified alongside oil and nuclear power and given eight years of tax credits. Google signed a 15-year contract, and Bill Gates committed $100 million. One company controls the entire supply chain behind this discovery.tc pixel

See the ticker behind this Grand Canyon energy breakthrough now
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
Initiated by$8.46
+1.0%
$18.00Outperform
Sylvamo Corporation stock logo
SLVM
Sylvamo
Initiated by$36.28
+4.0%
$47.00Equal WeightOverweight
Tarsus Pharmaceuticals, Inc. stock logo
TARS
Tarsus Pharmaceuticals
Initiated by$79.40
+1.5%
$110.00Overweight
TRAX
First Tracks Biotherapeutics
Initiated by$39.30
+2.1%
$100.00Buy
TRAX
First Tracks Biotherapeutics
Initiated by$39.30
+2.1%
Buy
TRAX
First Tracks Biotherapeutics
Initiated by $39.30
+2.1%
$100.00Buy
Zentalis Pharmaceuticals, Inc. stock logo
ZNTL
Zentalis Pharmaceuticals
Initiated by$3.07
-1.9%
Outperform

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Wednesday at 01:08 PM ET.

Frequently Asked Questions

Analyst ratings are the "buy" and "sell" labels, plus price targets, that investment researchers attach to specific securities. These ratings are based on financial data, earnings reports  and conversations with company executives.

Analyst ratings provide plenty of helpful information, but you shouldn't use an analyst's "buy" rating as the sole reason you purchase a security. Analysts aren't immune to conflicts of interest or outside parties' influence, so ensure you always understand why a stock was labeled a "buy" or "sell."

Ratings give investors the analyst's overall opinion about a particular stock and price targets based on the company's valuation and prospects. Analysts often attend conference calls, ask questions and provide in-depth information about companies that are difficult to acquire elsewhere.